Floatz logo

Fremanezumab

Brain Disorder

Hospital Clínico Universitario de Valladolidmonoclonal_antibodyPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Brain Disorder cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Donanemab
Eli Lilly and Company
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B
Tocilizumab
Zhujiang Hospital
Phase 3B

View all 41 →

Same molecule, other indications

Fremanezumab is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
74 / 100
View asset →
migraine without auraActive
BB
Indicative · Phase 4
65 / 100
View asset →
sleep disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →